The Parkinson Study Group (PSG) is a network of clinical trial sites and investigators focused on Parkinson’s disease. It aims to expand clinical trial opportunities and enhance the development of new treatments through collaborative research. Governed by an elected Executive Committee, PSG oversees various research projects, initiatives, and working groups to advance scientific inquiry and practical knowledge in the field of Parkinson’s disease.
1986
46-5749468
$1.103 million
This organization contributes to the following United Nations Sustainable Development Goals. See the SDG page for more information.
Join us for our annual meeting where investigators and clinical researchers discuss advancements in Parkinson's research.
PSG collaborates with various sites for clinical trials aimed at improving treatment options for Parkinson's disease.
Stay updated with the latest news and research through our monthly newsletters.
2024-12-05
Annual conference bringing together leaders in Parkinson's disease research.
Learn More2024-12-09
Deadline for applying for PSG credentialing.
Learn MoreOverall Score
62
62
/100
Program Expense Ratio
66.61%
6
/20
Program Revenue Growth
122.82%
20
/20
Leverage Ratio
0.01608
20
/20
Working Capital Ratio
2.258
14
/20
Fundraising Efficiency
0
2
/20
Fiscal Year:2021
Source:Source: Self-reported by organization
Category | Amount | Percentage |
---|---|---|
Contributions, Gifts, and Grants | 52.39K | 5.83% |
Program Services | 846.4K | 94.17% |
Investment Income | 0 | 0.00% |
Sales of Non-Inventory Assets | 0 | 0.00% |
Other Notable Sources | 0 | 0.00% |
Total Revenue | 898.8K | 100.00% |
Health Associations
Nerve/Muscle/Bone HealthHealth Associations
Nerve/Muscle/Bone HealthHealth Associations
Nerve/Muscle/Bone HealthHealth Associations
Nerve/Muscle/Bone HealthHealth Associations
Nerve/Muscle/Bone Health